Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.  Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance has been to crack the code of immunosuppression induced by cancer, especially via checkpoint inhibitors such as antibodies to CTLA4 and PD-1/PD-L1.  This has made many tumors amenable to immunotherapy.  However, the generalized nature of…

Read More

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered…

Read More

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Frank Borriello, CEO, Alloplex Biotherapeutics, regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. While there have been many advances in the field of cellular therapy in oncology, the common element limiting their adoption will be reproducibility of manufacturing, whether autologous or allogeneic, as well as generalizability across multiple tumor types, whether…

Read More

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

Read More

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

Washington D.C. [USA]: According to the Scientists, an autoimmune disease looks to be linked with testicular cancer that affects men. Known to us as ‘testicular cancer-associated paraneoplastic encephalitis’, it is the reason behind any serious neurological symptoms found in men. They lose control of the limbs, speech and eye movements progressively. The autoimmune disease starts with a testicular tumor, which seems to be the reason behind the immune system attacking the brain. Affected men find themselves undiagnosed or misdiagnosed often and relevant treatment is delayed. In a study that was published in…

Read More

Emerging 4 Trends – Cancer Immunotherapy Biomarkers

Emerging 4 Trends – Cancer Immunotherapy Biomarkers

Cancer immunotherapy has turned out to be a revolutionary treatment to fight against this largest group of diseases in the world. The artificial stimulation of the immune system enhances the natural ability of the body to fight against cancer. The field on immunotherapy shows a great potential in treating a wide range of types of cancers. Over 8,000 cancer immunotherapy experiments are taking place in clinical trials along with which includes rapid development of biomarkers. The smart and effective immunotherapy is already transforming cancer treatment approach while biomarkers, in addition,…

Read More